With the in-depth promotion of medical reform, domestic device enterprises look for certainty and high prosperity development opportunities in danger and opportunity
With the advancement of the new medical reform, some policies such as unified consumables coding, centralized procurement of consumables and DRG / Dip medical insurance payment have had a far-reaching impact on the supervision and operation of the medical device industry, reconstructed the product pattern of medical device manufacturers and changed the future development strategy. Chinese manufacturers closely follow the pace of national health care reform, look for deterministic tracks, actively promote technology upgrading, innovation iteration and domestic substitution, and actively seek opportunities to go to sea.
Medical device enterprises will look for breakthrough opportunities and open market space under DRG / dip and centralized purchase policies
(1) DRG / Dip policy will be conducive to the large amount of postoperative auxiliary consumables. The policy does not limit the payment for treatment outside the hospital, so you can find opportunities in post discharge auxiliary consumables; (2) Innovative products and techniques will be promising. For innovative products and techniques, local government departments can declare special fees; (3) Accelerate the promotion of graded diagnosis and treatment, and the testing market of secondary hospitals has been opened. According to the patient situation and the hospital system process, the unhealed patients can be pushed to the secondary hospital for rehabilitation treatment, and the rehabilitation nursing consumables and testing equipment of the secondary hospital will be organically available; (4) Under the total payment of DRG / dip, the centralized purchase and price reduction of specific surgical methods and some high-value consumables will be carried out, and the price reduction space will be left to the market of minimally invasive new and detection methods. (5) The volume of daytime surgery will also be greatly increased, and the equipment and consumables space in the operating room will be opened. In order to meet the payment policy requirements, the daytime operating room will undertake some inpatient operations. The hospital is expected to open more outpatient operating rooms, the full set of equipment in the process of building the operating room system will be added, and the necessary consumables for surgery are expected to be in large quantities. (6) Minimally invasive surgery can shorten hospital stay and improve bed turnover. The proportion of endoscopic surgery will increase, and endoscopic products will benefit.
Domestic imaging equipment, high-value consumables, in vitro diagnosis, interventional surgery and other markets are expected to usher in large quantities
(1) under the DRG / Dip + graded diagnosis and treatment policy, the testing equipment is expected to be large, such as x-ray imager; (2) Under the maternity policy, the maternal and Child Rehabilitation examination market is expected to usher in a second prosperity, such as rehabilitation equipment, color Doppler ultrasound, etc; (3) Affected by the aging of population structure, the improvement of health awareness, the improvement of medical quality and technological progress, the in vitro diagnosis industry and household medical equipment show a rapid development trend; (4) The innovative surgery market focuses on the vascular intervention and electrophysiological surgery market with low domestic rate, large import substitution opportunities and continuous prosperity. With the improvement of disease detection and diagnosis rate in the field of intervention and the continuous improvement of clinical experience, the market scale of interventional medical devices in China is expected to continue to grow, and interventional medical enterprises will continue to benefit from market expansion. (5) Life science polymer consumables suppliers benefit from centralized procurement and volume increase and globalization. The polymer consumables industry has a high-quality ODM business model, and its performance will usher in a large-scale period.
Recommended and beneficial objects
We suggest exploring investment opportunities from two perspectives: first, policy beneficiaries such as centralized procurement, and the recommended target is the life science polymer consumables provider Shenzhen Changhong Technology Co.Ltd(300151) ; Second, there may be negative policy impact in the short term, but in the long term, through medical equipment and device companies that meet the new clinical needs and have the ability of domestic substitution and globalization, the recommended target: Xiangyumedicalco.Ltd(688626) ; Beneficiaries: Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) , Beijing Wandong Medical Technology Co.Ltd(600055) , Autobio Diagnostics Co.Ltd(603658) , Guangzhou Wondfo Biotech Co.Ltd(300482) , minimally invasive Siasun Robot&Automation Co.Ltd(300024) , Jiangsu Yuyue Medical Equipment And Supply Co.Ltd(002223) , Shenzhen Lifotronic Technology Co.Ltd(688389) , minimally invasive medical treatment, Lepu Medical Technology (Beijing) Co.Ltd(300003) , Shanghai Kindly Enterprises Development Group Co.Ltd(603987) medical equipment, Shanghai Microport Endovascular Medtech (Group) Co.Ltd(688016) , Xinwei medical treatment, Kontour(Xi'An) Medical Technology Co.Ltd(688314) , etc.
Risk tip: the policy promotion is less than expected, and the price reduction of centralized purchase is more than expected.
